Home > Insider Trading > Filing (0001209191-13-045272)

Filing Details

Accession Number:: 0001209191-13-045272
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-09-23 17:01:16
Reporting Period:: 2013-09-19

Filing Date:: 2013-09-23
Accepted Time:: 2013-09-23 17:01:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1427925	Acelrx Pharmaceuticals Inc	ACRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1198330	P Guy Nohra	One Embarcadero Center 37Th Floor San Francisco CA 94111		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-09-19	61,634	$10.21	2,604,493	No	4	S	Indirect	ACP IV, L.P.
Common Stock	Disposition	2013-09-20	96,519	$10.84	2,507,974	No	4	S	Indirect	ACP IV, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	ACP IV, L.P.
No	4	S	Indirect	ACP IV, L.P.

Footnotes

The shares reported hereby were sold pursuant to a Rule 10b5-1 plan adopted by Alta on September 6, 2013, which represents the sale of all remaining shares covered by the plan.
The price reported in Column 4 is a weighted average price. The range of sale prices for the transactions reported was $10.10 to $10.40 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The shares are owned by ACP IV, L.P. ("ACPIV"). ACMP IV, LLC (the "General Partner") serves as the general partner of ACPIV, L.P. and possesses power to direct the voting and disposition of the shares owned by ACPIV and may be deemed to have indirect beneficial ownership of the shares held by ACPIV. The General Partner owns no securities of the Issuer directly. The Reporting Person is a member of the General Partner. As such, the Reporting Person shares voting and investment power over the shares held by ACPIV. The Reporting Person disclaims beneficial ownership of the shares held by ACP IV except to the extent of his proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. The range of sale prices for the transactions reported was $10.48 to $11.14 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.